IGC Pharma adds New York site for Alzheimer’s disease trial

​IGC Pharma has expanded its CALMA Phase II clinical trial by adding Integrative Clinical Trials, based in Brooklyn, New York, US, as a new site evaluating IGC-AD1 for agitation associated with AD.

The post IGC Pharma adds New York site for Alzheimer’s disease trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Philips unveils new InkSpace Snuggle coil for paediatric imaging
Lyell doses first patient in Phase III trial for LBCL
Natus Sensory acquires medical technology company TheraB Medical
MSD receives FDA approval for Keytruda combo to treat ovarian cancer
Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us